Chamber and committees

This information is not centrally held. While the Scottish Government’s role is to set the strategic policy for the NHS in Scotland, NHS Boards and healthcare professionals locally have responsibility for both service delivery and people’s care. NHS Boards are expected to ensure that patients, including those who require care and support for ME/CFS, have access to a range of professionals to provide the appropriate management of their condition.

Given the range of symptoms which can be experienced with ME/CFS, we know there is no ‘one-size fits all’ response and our approach is to support people to access care and support in a setting that is appropriate and as close to their home as is practicable.

Our strengthening of the primary care workforce through recruitment of multi-disciplinary teams is making it easier for people to access this type of care and support. We have now recruited over 3,220 professionals, including community nurses and physiotherapists, with increased funding of £170m in 2022-23 to support further development of multi-disciplinary teams.

The Scottish Government co-funds and participates in the Perinatal Audit and Perinatal Mortality Review Tool as part of Mothers and Babies, Reducing Risk through Audits and Confidential Enquiries across the UK (MBRRACE-UK).

The Scottish Government continues to support implementation of The Best Start programme, in partnership with senior leaders and clinicians, and evidence suggests that Best Start interventions such as continuity of carer are particularly important for women and babies who may experience inequalities in health outcomes. Scotland has a programme of work underway to tackle racialized inequalities in health outcomes, and NHS maternity services are part of that work. Scotland also participates in the Royal College of Obstetricians and Gynaecologists’ Race Equality Taskforce .

We welcome the recommendations made within the recent Scottish stakeholder review of the ME/CFS NICE guideline and are working with stakeholders on how best to implement these. The report was produced independently by Blake Stevenson Ltd to present the views gathered during a stakeholder engagement exercise commissioned by the Scottish Government.

The independent economic regulator, the Water Industry Commission for Scotland (WICS), produces the average charge data in Scotland. In England and Wales, Water UK provides the data to Discover Water. Both average charges are produced independent of water companies and represent the best comparator available.

As set out in the response to S6W-08912, the Final Determination explained that the Commission would expect that its charge caps would allow Scottish Water’s annual revenue in the final year of the current regulatory control period to be no less than £1,392m (as set out in page 10 of the Final Determination). This level of revenue was based on assuming an average charge cap of 1.5% a year above inflation over the regulatory control period 2021-27.

The Final Determination set a maximum amount of charges of CPI + 2% on average for each year of the regulatory control period. As set out in the Final Determination, the difference between the CPI + 2% and the CPI + 1.5% each year on average was to cover any additional costs that Scottish Water incurs in selecting an investment option that has a higher net present value than the lowest financial cost option, after allowing for externalities such as carbon, natural and social capital. This is the allowance of £132m set out in pages 9 and 15 of the Final Determination. This money would only be used where such projects had been thoroughly appraised. The minimum revenue expectation did not take account of this allowance.

We are still modelling potential structures based on updated scheme membership data and plan to engage with the Scheme Advisory Board on these shortly. The previous proposals we consulted on put forward broadly similar rates for lower earners to those in the contribution structure implemented in England and Wales.

When developing the structure, protecting lower earners from large increases in contribution rates is a key driver but has to be balanced against the legal imperative to begin to reduce the very highest rates and flatten the contribution structure. The biggest challenge in comparing against the rates in England and Wales is that there is a bigger yield shortfall to recover in the Scottish scheme, principally due to workforce demographics.

The Scottish Government welcomes continued engagement with health service unions in developing appropriate proposals on pension issues. We are currently modelling member contribution rate structures for the NHS Pension Scheme (Scotland) and will shortly be consulting with the NHS Pension Scheme Advisory Board before holding a public consultation on proposals towards the end of this year.

The Scottish Government is not aware of any practice by pharmacy chains offering work to Scottish locum pharmacists in other parts of the UK while agreeing to closures across the Scottish pharmacy network.

Neither the Scottish Government or Health Boards are responsible for the terms or contractual arrangements put in place between pharmacy businesses and those who provide a pharmacy locum service.

All payments as part of the national contractual framework are published annually. The latest iteration can be found at SHOW - Scotlands Health On the Web - Publications, including payments for non-activity based services delivered as part of the Pharmaceutical Services Remuneration Global Sum.

Health Boards can recover remuneration in line with the measures available as set out in the National Health Service (Pharmaceutical Services) (Scotland) Regulations 2009 and the National Health Service (Discipline Committees) (Scotland) Regulations 2006.

The Scottish Government holds routine and ongoing discussions with all Health Board Directors of Pharmacy on a range of operational and policy issues regarding the delivery of NHS Pharmaceutical Care services. These include discussions on any proposed changes to contractual framework arrangements as set out in the Achieving Excellence in Pharmaceutical Care strategy recommendations.